Skip Navigation
Skip to contents
Results by Year

View Wide

Filter

ARTICLE TYPE

PUBLICATION DATE

86 results
Display

Retrospective analysis of intensity-modulated radiotherapy and three-dimensional conformal radiotherapy of postoperative treatment for biliary tract cancer

Lee HC, Lee JH, Lee SW, Lee JH, Yu M, Jang HS, Kim SH

PURPOSE: This study was conducted to compare the outcome of three-dimensional conformal radiotherapy (3D-CRT) and intensity-modulated radiotherapy (IMRT) for the postoperative treatment of biliary tract cancer. MATERIALS AND METHODS: From February...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Safety Evaluation of Paclitaxel-Eluting Biliary Metal Stent with Sodium Caprate in Porcine Biliary Tract

Jang SI, Jeong S, Lee DH, Na K, Yang S, Lee DK

BACKGROUND/AIMS: Metallic stents designed to relieve malignant biliary obstruction are susceptible to occlusive tumor ingrowth or overgrowth. In a previous report, we described metallic stents covered with paclitaxel-incorporated membrane (MSCPM-I,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer

Nam AR, Jin MH, Park JE, Bang JH, Oh DY, Bang YJ

PURPOSE: The DNA damage response (DDR) is a multi-complex network of signaling pathways involved in DNA damage repair, cell cycle checkpoints, and apoptosis. In the case of biliary tract cancer...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin

Hyung J, Kim B, Yoo C, Kim KP, Jeong JH, Chang HM, Ryoo BY

PURPOSE: Gemcitabine plus cisplatin (GemCis) is the standard first-line chemotherapy for patients with advanced biliary tract cancer (BTC). In ABC-02 study, the BTC patients received up to 6-8 cycles of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer

Nam AR, Kim JW, Park JE, Bang JH, Jin MH, Oh DY, Bang YJ

PURPOSE: Jab1 is a coactivator of c-Jun that enhances the transcriptional function of c-Jun. Jab1 is frequently overexpressed in various cancers and is associatedwith poor prognosis of cancer patients. Thus,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Incidence and Overall Survival of Biliary Tract Cancers in South Korea from 2006 to 2015: Using the National Health Information Database

Kim BW, Oh CM, Choi HY, Park JW, Cho H, Ki M

BACKGROUND/AIMS: There have been no nationwide studies to investigate the trends in incidence and 5-year survival rates of intra- and extrahepatic bile duct cancers and gall-bladder cancer. Therefore, our study...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Somatic Mutations from Whole Exome Sequencing Analysis of the Patients with Biliary Tract Cancer

Yoon KA, Woo SM, Kim YH, Kong SY, Han SS, Park SJ, Lee WJ

Biliary tract cancer (BTC) is a rare cancer and is associated with a poor prognosis. To understand the genetic characteristics of BTC, we analyzed whole-exome sequencing data and identified somatic...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Imaging diagnosis of extrahepatic biliary tract obstruction with acquired portosystemic shunt in a cat

Hwang TS, Jang WS, Yoon YM, Jung DI, Lee HC

A 2-year-old, spayed female, Korean domestic short-hair cat was presented with depression and vomiting. The patient had history of weight loss lasting seven months. Physical examination revealed icterus in the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Thromboembolic Events as Prognostic Clinical Markers in Advanced Pancreatic and Biliary Tract Cancer

Shin K, Lee MA

BACKGROUND/AIMS: Venous thromboembolic events (VTEs) are common events in patients with advanced cancer. We analyzed the clinical characteristics of VTEs in advanced pancreatic and biliary tract cancer to determine the...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-line Treatment for Patients with Recurrent or Metastatic Biliary Tract Cancer

Yoo C, Han B, Kim HS, Kim KP, Kim D, Jeong JH, Lee JL, Kim TW, Kim JH, Choi DR, Ha HI, Seo J, Chang HM, Ryoo BY, Zang DY

PURPOSE: Although gemcitabine plus cisplatin has been established as the standard first-line chemotherapy for patients with advanced biliary tract cancer (BTC), overall prognosis remains poor. We investigated the efficacy of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Chemotherapy versus Best Supportive Care in Advanced Biliary Tract Carcinoma: A Multi-institutional Propensity Score Matching Analysis

Ji JH, Kim YS, Park I, Lee SI, Kim RB, Park JO, Oh SY, Hwang IG, Jang JS, Song HN, Kang JH

PURPOSE: Although chemotherapy is recommended by various guidelines for advanced biliary tract cancer (BTC), the evidence supporting its use over best supportive care (BSC) is limited. The aim of this...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Liver Fluke-Associated Biliary Tract Cancer

Prueksapanich P, Piyachaturawat P, Aumpansub , Ridtitid W, Chaiteerakij R, Rerknimitr R

Cholangiocarcinoma (CCA) is an aggressive cancer arising from epithelial cells of the bile duct. Most patients with CCA have an unresectable tumor at the time of diagnosis. In Western countries,...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Comparison of Outcomes between 7-French and 10-French Plastic Stents for Patients with Biliary Tract Cancer

Lee KJ, Kang YS, Seong JH, Jung S, Kim JW

BACKGROUND/AIM: There is little data on whether plastic stents with a larger diameter are patent for longer than small stents in patients with bile duct cancer. The aim of this...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Prognostic Factors and Scoring Model for Survival in Metastatic Biliary Tract Cancer

Park HS, Park JS, Chun YJ, Roh YH, Moon J, Chon HJ, Choi HJ, Park JS, Lee DK, Lee SJ, Yoon DS, Jeung HC

PURPOSE: Metastatic biliary tract cancer (mBTC) has a dismal prognosis. In this study, an independent dataset of patients with mBTC was used to implement and validate a routine clinico-laboratory parameter-based...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
CA19-9 or CEA Decline after the First Cycle of Treatment Predicts Survival in Advanced Biliary Tract Cancer Patients Treated with S-1 and Cisplatin Chemotherapy

Lee DW, Im SA, Kim YJ, Yang Y, Rhee J, Na II, Lee KH, Kim TY, Han SW, Choi IS, Oh DY, Kim JH, Kim TY, Bang YJ

PURPOSE: While tumor markers (carbohydrate antigen 19-9 [CA 19-9] and carcinoembryonic antigen [CEA]) can aid in the diagnosis of biliary tract cancer, their prognostic role has not been clearly elucidated....
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Chemotherapy for Biliary Tract Cancer

Woo SM

The term of biliary tract cancer (BTC) refers to all tumors that arise from the biliary tract or the biliary drainage system, including the intra- and extra-hepatic bile ducts as...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Clinical implications of APEX1 and Jagged1 as chemoresistance factors in biliary tract cancer

Kim HB, Cho WJ, Choi NG, Kim SS, Park JH, Lee HJ, Park SG

PURPOSE: Biliary cancer is a highly malignant neoplasm with poor prognosis and most patients need to undergo palliative chemotherapy, however major clinical problem associated with the use of chemotherapy is...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Metastasectomy for Recurrent or Metastatic Biliary Tract Cancers: A Single Center Experience

Kim J, Jang Y, Shim J, Yu J, Shin DB, Park I

OBJECTIVE: Efficacy or long-term result of metastasectomy for recurrent or metastatic biliary tract carcinoma (BTC) is not well established. We conducted a retrospective review of the outcomes of metastasectomy for...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Second-Line Chemotherapy in Advanced Biliary Tract Cancer: A Retrospective Analysis

Kim HJ, Yun J, Kim HJ, Kim KH, Kim SH, Lee SC, Bae SB, Kim CK, Lee NS, Lee KT, Park SK, Won JH, Choi HJ, Moon JH, Hong DS

OBJECTIVE: The evidence of 2nd line chemotherapy has not been validated. We investigated the treatment outcomes of 2nd line palliative chemotherapy in patients with biliary tract cancer (BTC) and analyzed...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Advanced Imaging Technology in Biliary Tract Diseases:Narrow-Band Imaging of the Bile Duct

Choi HJ, Moon JH, Lee YN

Newly introduced direct peroral cholangioscopy and the development of video choledochoscopes have enabled more defined observation of bile duct mucosal lesions with clearer images. Narrow-band imaging (NBI) is a unique...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr